Document:

Prepared by R.R. Donnelley Financial -- Assignment

 EXHIBIT 10.21 
  
 ASSIGNMENT 
  
 THIS ASSIGNMENT (this Assignment) is made and entered into this 8th day of June, 2000 by and
among Baxter Healthcare Corporation, a Delaware corporation (Baxter), Baxter International Inc., a Delaware corporation (BII and, together with Baxter, the Assignors) and GenStar Therapeutics Corporation (formerly known as UroGen Corp.), a Delaware
corporation (Assignee). 
  
 WHEREAS, Assignors together own or hold the rights to all of the intellectual property listed on
Exhibit A attached hereto, together with any registrations and applications therefor (collectively, the Property Assets); 
  
 WHEREAS, pursuant to the Asset Purchase Agreement, dated February 28, 1998, by and between Baxter and Assignee, as amended by that Amendment No. 1 to Asset Purchase Agreement, dated as of May 27, 1998 between Baxter and Assignee (as
amended, the Asset Purchase Agreement) and pursuant to the Technology License Agreement dated July 8, 1998, between BII and Assignee (the License Agreement), Baxter has agreed to assign, and to cause its parent company BII to assign, all of their
right, title and interest in and to the Intellectual Property Assets to Assignee upon Assignee’s achievement of the Investment Milestone (as such term is defined in the Asset Purchase Agreement); 
  
 WHEREAS, Assignee has informed Assignors that it has achieved the Investment Milestone and desires to have the Intellectual Property Assets assigned to
Assignee; 
  
 WHEREAS, Assignors and Assignee are desirous of memorializing the transfer of the Intellectual Property Assets to
Assignee. 
  
 NOW, THEREFORE, Assignors, for good and valuable consideration set forth in the Asset Purchase Agreement and the
License Agreement, the receipt and sufficiency of which is hereby acknowledged, does hereby assign and transfer to Assignee, all of Assignors’ right, title and interest in and to the Intellectual Property Assets, together with all
continuations, in whole or in part, divisions, reissues, renewals and extensions of any such Intellectual Property Assets as of the date hereof. Assignors do hereby further consent to the recordation of this Assignment by Assignee with the
Commissioner of Patents and Trademarks of the United States, with any other appropriate U.S. agency and any appropriate foreign government, agency or commission. 
  
 Assignors and Assignee agree that this Assignment is intended solely to memorialize the transfer of Assignors’ rights in and to the Intellectual Property Assets to Assignee
resulting from the transaction described in the Asset Purchase Agreement. All representations and warranties related to the Intellectual Property Assets are contained in the Asset Purchase Agreement and no additional representations or warranties
are made or intended to be made herein. 
 

  
 IN WITNESS WHEREOF, the parties hereto have executed this Assignment as of the date first
written above. 
  
 
	 BAXTER HEALTHCARE CORPORATION (Assignor)
 
	 
	 By:
 	 	 

	 Title:
 	 	 

 
  
 
	 BAXTER INTERNATIONAL INC. (Assignor)
 
	 
	 By:
 	 	 

	 Title:
 	 	 

 
  
 
	 GENSTAR THERAPEUTICS CORPORATION (“Assignee”)
 
	 
	 By:
 	 	 

	 Title:
 	 	 

 
 

 ii 

  
 EXHIBIT A 
  
 Intellectual Property Assets 
  
 A.    All of
Assignors’: 
  

	 	1.
	 
	United States and foreign copyrights, whether registered or unregistered; 
 

  

	 	2.
	 
	United States, state and foreign trademarks, services marks, logos, trade dress and trade names, whether registered or unregistered; 
 

  

	 	3.
	 
	confidential ideas, trade secrets, technology, know-how, inventions (whether or not patentable) and improvements thereto, concepts, methods, processes, formulae, reports, data,
customer lists, mailing lists, business plans or other proprietary information; and 
 

  

	 	4.
	 
	computer software programs and software systems, including, without limitation, all database applications, compilations, tools sets, compilers, higher level or proprietary
languages, related documentation and materials, whether in source code, object code or human readable form, 
 

  
 which exclusively relate
to the technology developed by Baxter and relating to the mini adenoviral vectors for gene therapy, and any goodwill relating exclusively thereto. 
  
 B.    The following patent applications: 
  

	 	1.
	 
	MINI-ADENOVIRAL VECTOR SYSTEM 
 

  

	 	•
	 
	U.S. Ser. No. 08/658,961 filed May 31, 1996 
 

  

	 	2.
	 
	FACTOR VIII MINI-AD VECTOR 
 

  

	 	•
	 
	U.S. Ser. No. 08/791,218 filed January 31, 1997 (CIP of 08/658,961) 
 

  

	 	•
	 
	PCT/US97/10218 filed May 30, 1997 (based on 08/791,218 and 08/658,961) 
 

  

	 	•
	 
	European App. No. EP 979289618 
 

  

	 	•
	 
	Canadian App. No. 2257148 
 

  

	 	•
	 
	Japan App. No. JP 9-543095 
 

  

	 	3.
	 
	MINI-AD VECTOR, U.S. Ser. No. 08/866,403 filed May 30, 1997 (CIP of 08/791,218 and 08/658,961) 
 

  

	 	4.
	 
	ONCOLYTIC/IMMUNOGENIC COMPLEMENTARY ADENOVIRAL VECTOR SYSTEM 
 

  

	 	•
	 
	U.S. Ser. No. 08/797,160 filed February 10, 1997 
 

  

	 	•
	 
	U.S. Ser. No. 09/539,698 filed March 31, 2000 (CIP of 08/797,160) 
 

  

	 	•
	 
	PCT/US98/01301 filed January 23, 1998. National phase applications: 
 

  

	 	•
	 
	European App. No. EP 98904658.6 
 

  

	 	•
	 
	Canadian App. No. 2280237 
 

 

 -iii- 

  

	 	•
	 
	Japan App. No. JP 10534738 
 

  

	 	5.
	 
	ADENOVIRUS E1-COMPLEMENTING CELL LINES 
 

  

	 	•
	 
	U.S. 08/810,039 filed March 4, 1997 
 

  

	 	•
	 
	PCT/US98/03473 filed February 23, 1998. National phase applications: 
 

  

	 	•
	 
	European App. No. EP 98908661.6 
 

  

	 	•
	 
	Canadian App. No. 2283253 
 

  

	 	•
	 
	Japan App. No. JP 1053874 
 

  

	 	6.
	 
	METHOD FOR HIGHLY EFFICIENT GENERATION OF ADENOVIRAL VECTORS 
 

  

	 	•
	 
	U.S. Ser. No. 08/789,886 filed January 28, 1997 
 

  

	 	•
	 
	PCT/US97/23685 filed December 19, 1997 (national phase not entered) 
 

  

	C.    Any
	 
	(i) inventions which may have been made and in which Baxter owns rights pursuant to the Clinical Studies Agreement between McMaster University and Baxter dated April 4, 1996;
and (ii) inventions relating to adenoviral vector which may have been made or which are made in the future, and in which Baxter owns rights pursuant to the July 1, 1996 agreement between Baxter and the Chinese Academy of Military Medical Services.

 

 

 -iv-Prepared by R.R. Donnelley Financial -- Common Stock Purchase Warrant

  
 EXHIBIT 10.22 
  
 NEITHER THIS WARRANT NOR THE SHARES ISSUABLE UPON THE EXERCISE HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR STATE SECURITIES LAWS. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT
ONLY AND NOT WITH A VIEW TO, OR IN CON­NECTION WITH, THE SALE OR DISTRIBUTION THEREOF. THESE SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL REASON­ABLY
ACCEPTABLE TO IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT AND IS IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS WARRANT AND THE SHARES ISSUABLE UPON THE EXERCISE
HEREOF ARE SUBJECT TO CERTAIN RESTRICTIONS ON THEIR TRANSFER PURSUANT TO TERMS SET FORTH IN THIS WARRANT. 
  
 Warrant to Purchase Shares

 of Common Stock 
 (Subject to Adjustment) 
  
 UROGEN CORP. 
  
 COMMON STOCK PURCHASE WARRANT 
 Void after February 27, 2005 
  
 UroGen Corp., a Delaware corporation (the “Company”), hereby
certifies that, for value received, Baxter Healthcare Corporation, or its permitted assigns, is entitled, subject to the terms set forth below, to purchase from the Company at any time or from time to time before 5:00 p.m. Pacific time, on February
28, 2005 (the “Expiration Time”), 100,000 fully paid and nonassessable shares of Common Stock of the Company at a purchase price per share equal to the Warrant Price (as defined herein) and otherwise in accordance with the terms hereof.
The number and character of such shares of Common Stock and the Warrant Price therefor are subject to adjustment as provided below. 
  
 As used herein the
following terms, unless the context otherwise requires, have the following respective meanings: 
  
 (a)  The term
“Company” shall mean Urogen Corp. and any corporation that shall succeed to or assume the obligations of the Company hereunder. 
  
 (b)  The term “Control Transaction” shall mean (i) the sale by the Company of all or substantially all of its assets or (ii) any transaction or series of related transactions by the Company
(including, without limitation, any reorganization, merger or consolidation) which results in the transfer of at least fifty percent (50%) of the outstanding voting power of the Company; provided, however, that a reorganization, merger
or similar transaction shall not be deemed a Control Transaction if the stockholders of the Company immediately prior to such 
 

 -C1- 

 transaction maintain beneficial ownership and voting control of a majority of the outstanding voting securities of the surviving entity in the same relative
proportions as they did prior to such transaction. 
  
 (c)  The term “holder” shall mean the holder of this
Warrant or any permitted transferee or assignee thereof. 
  
 (d)  The term “Original Issuance Date” shall mean
February 28, 2000. 
  
 (e)  The term “Warrant” shall mean this Warrant. 
  
 (f)  The term “Warrant Price” shall mean $2.00 per share. 
  
 (g)  The term “Warrant Shares” shall mean the shares of Common Stock or other securities of the Company issuable upon exercise of this Warrant, subject to adjustment
hereunder from time to time. 
  
 1.    Initial Exercise Date; Expiration.    This
Warrant may be exercised in full at any time prior to the Expiration Time, and shall expire immediately thereupon. Notwithstanding the foregoing, this Warrant shall expire and no longer be exercisable immediately prior (and subject to) the closing
of any Control Transaction. The Company shall provide the holder of this Warrant with at least 15 days prior notice of the occurrence of any event that would constitute a Control Transaction. 
  

2.    Exercise of Warrant. 
  
 (a)  This Warrant may be exercised in full by the holder hereof by surrender of this Warrant, with the form of subscription attached hereto duly executed by such holder, to the Company at its principal
office, accompanied by payment in accordance with Section 2(b) hereof, of the aggregate Warrant Price of the Warshy;rant Shares to be purchased hereunder. 
  
 (b)  In lieu of payment in cash, payment of the aggregate Warrant Price upon exercise of the Warrant may be made by (i) surrender to the Company of debt or
equity securities of the Company having a fair market value equal to the aggregate exercise price of the Warrant Shares being purchased upon such exercise (provided that for purposes of this subparagraph, the fair market value of the Common Stock
shall equal the Market Price of the Common Stock as set forth below, and the fair market value of any note or other debt security shall be deemed to be equal to the aggregate outstanding principal amount thereof plus all accrued and unpaid interest
thereon) or (ii) delivery of a written notice to the Company that the holder is exercising the Warrant by authorizing the Company to withhold from issuance a number of Warrant Shares issuable upon such exercise of the Warrant which when multiplied
by the Market Price (as set forth below) is equal to the aggregate Warrant Price of the Warrant Shares being purchased upon such exercise (and such withheld shares shall no longer be issuable under this Warrant). 
  
 (c)  The Market Price of the Company’s Common Stock as of a particular date (the “Determination Date”) shall
be calculated as follows: 
 

 -C2- 

  
 (i)  If the Company’s Common Stock is traded on an exchange or
is quoted on the National Association of Securities Dealers, Inc. Automated Quotation (“Nasdaq”) National Market System, then the average of the closing or last sale prices, respectively, reported for the twenty (20) business days
immediately preceding the Determination Date; 
  
 (ii)  If the Company’s Common Stock is not
traded on an exchange or on the Nasdaq National Market System but is traded in the over-the-counter market, then the average of the means of the closing bid and asked prices reported for the twenty (20) business days immediately preceding the
Determination Date; 
  
 (iii)  If the Company’s Common Stock is not traded on an exchange, on the
Nasdaq National Market System or in the over-the-counter market, then the fair market value of the Common Stock as of the day immediately preceding the Determination Date, as determined by the Company’s board of directors in good faith.

  
 3.    When Exercise Effective.    The exercise of this Warrant shall be deemed
to have been effected immediately prior to the close of business on the business day on which the holder surrenders this Warrant to the Company and satisfies all of the requirements of Section 2, and at such time the person in whose name any
certificate for Warrant Shares ­shall be issuable upon such exercise, as provided in Sec­tion 2, shall be deemed to be the record holder of such Warrant Shares for all purposes. 
  
 4.    Delivery on Exercise.    As soon as practicable after the exercise of this Warrant, the Company at its expense will cause to be
issued in the name of and delivered to the holder hereof, or as such holder may direct, a certificate or certif­i­cates for the number of fully paid and nonassessable full Warrant Shares ­as to which such holder shall be entitled on such
exer­cise, together with cash, in lieu of any fraction of a Warrant Share, equal to such fraction of the Market Price of one full share of Common Stock. 
  
 5.    Adjustment of Warrant Price and Number of Warrant Shares.    Notwithstanding anything to the contrary in this Warrant: 
  
 (a)  Adjustments.    The Warrant Price per share shall be subject to adjustment from time to time
as follows: 
  
 (i)  Stock Splits and Stock Dividends.    If the number of
shares of Common Stock outstanding at any time after the Original Issuance Date is increased by a stock dividend payable in shares of Common Stock or by a subdivision or split-up of shares of Common Stock, then, on the date such payment is made or
such change is effective, the Warrant Price per share shall be proportionately decreased and the number of Warrant Shares shall be increased in proportion to such increase of out­standing shares. Such adjustment shall become effective at the
close of business on the date the dividend, subdivision or split-up becomes effective. 
  
 (ii)  Reverse Stock Splits.    If the number of shares of Common Stock outstanding at any time after the Original Issuance Date is decreased by a combination of the 
 

 -C3- 

 outstanding shares of Common Stock, then, on the effective date of such combination, the Warrant Price per share shall be
proportionately increased and the number of Warrant Shares shall be decreased in proportion to such decrease in outstanding shares. Such adjustment shall become effective at the close of business on the date the combination becomes effective.

  
 (iii)  Reorganization; Reclassification.    Subject to the expiration
provisions of Section 1 hereof, in the case, at any time after the Original Issuance Date, of any capital reorganization, or any reclassification of the stock of the Company (other than as a result of a stock dividend or subdivision, split-up or
combination of shares), the consolidation or merger of the Company with or into another person (other than a consolidation or merger in which the Company is the continuing entity and which does not result in any change in the Common Stock), or a
sale or transfer of all or substantially all of the Company’s assets, this Warrant shall, after such reorganization, reclassification, consolidation, merger or sale, be exercisable for the kind and aggregate number of shares of stock or other
securities or property of the Company or other entity to which the Holder would have been entitled if, immediately prior to such reorganization, reclassification, consolidation, merger or sale, such Holder had exercised this Warrant in full (subject
to all adjustments under this Section 5). The provisions of this clause (vi) shall similarly apply to successive reorganizations, reclassifications, consolidations, mergers or sales. 
  
 (iv)  All calculations under this Subsection (a) shall be made to the nearest cent or to the nearest one hundredth (1/100) of a share, as appropriate.

  
 (b)    Minimal Adjustments.    No adjustment in the Warrant
Price per share need be made if such adjustment would result in a change in the Warrant Price per share of less than $0.01. Any adjustment of less than $0.01 which is not made shall be carried forward and shall be made at the time of and together
with any subsequent adjustment which, on a cumulative basis, amounts to an adjustment of $0.01 or more in the Warrant Price per share. 
  
 6.    Notice of Adjustments.    Whenever the number of Warrant Shares or the Warrant Price per share shall be adjusted pursuant to Section 5 hereof, the Company shall provide notice by first
class mail to the holder of this Warrant setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the number of Warrant Shares and the Warrant
Price per share after giving effect to such adjustment. 
  
 7.    No
Impairment.    The Company (a) will not increase the par value of any shares of stock receiv­able on the exercise of this Warrant above the amount payable there­for on such exercise, (b) will at all times reserve and
keep available a number of its authorized shares of Common Stock, free from all preemptive rights therein, which will be sufficient to permit the exercise of this Warrant, and (c) shall take all such action as may be necessary or appropriate in
order that all Warrant Shares as may be issued pursuant to the valid exercise of this Warrant will, upon issuance, be duly and validly issued, fully paid and nonassessable and free from all taxes, liens and charges with respect to the issue thereof.

 

 -C4- 

  
 8.    Exchange of Warrants.    Subject to the
provisions of Section 9 below, on surrender for exchange of this Warrant, properly endorsed, to the Company, the Company at its expense will issue and deliver to or on the order of the holder thereof a new Warrant of like tenor, in the name of such
holder or as such holder may direct, calling in the aggregate on the face thereof for the number of Warrant Shares called for on the face of the Warrant so surrendered. 
  
 9.    Replacement of Warrants.    On receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or
mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, on surrender
and cancellation of such Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor. 
  
 10.    Investment Intent.    The holder hereof, by accepting this Warrant, cove­nants and agrees that, at the time of exercise hereof, and at the time of any proposed transfer of the
Warrant Shares, such holder will deliver to the Company a written statement that the securities acquired by the holder upon exercise hereof are for the account of the holder for investment and are not acquired with a view to, or for sale in
connection with, any dis­tribution thereof (or any portion thereof) and with no present intention (at any such time) of offering and distributing such securities (or any portion thereof), and make other representations which the Company may
reasonably require in order to comply with the restrictions of state and federal securities laws relating to the sale and disposition on “restricted securities,” as that term is defined in Rule 144 of the Securities Act. 

 
 11.    Transfer Restrictions.    The holder hereof acknowledges that the Warrants and Warrant
Shares may not be transferred except in accordance with Section 5.1 of the Agreement. 
  
 12.    Notices.    All notices referred to in this Warrant shall be in writing and shall be delivered personally (including by express courier) or by first class mail, and will be deemed to
have been given when so delivered or mailed (i) to the Company, at its principal executive offices and (ii) to the holder of this Warrant, at such holder’s address as it appears in the records of the Company (unless otherwise indicated by such
holder). 
  
 13.    Miscellaneous.    This Warrant and any term hereof may be
changed, waived, discharged or terminated in accordance with Section 7.1 of the Agreement. This Warrant shall be governed by and construed and enforced in accor­dance with the internal laws of the State of California. The headings in this
Warrant are for pur­poses of reference only, and shall not limit or otherwise affect any of the terms hereof. 
  
 [This Space
Intentionally Left Blank] 
 

 -C5- 

  
 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed and attested by its duly
authorized officers and to be dated February 28, 2000. 
  

	 	UR
	OGEN CORP. 
 

  

	 	By
	:                                      
                                        
     
 

	 	       
	   Paul D. Quadros 
 

	 	    
	    Chairman and Chief Financial Officer 
 

  
 [Signature Page to Purchase Warrant] 
 

  
 FORM OF SUBSCRIPTION 
  
 (To be signed only on exercise of Warrant) 
  
 TO: UroGen Corp. 
  
 The undersigned, the holder of the within Warrant, hereby irrevocably elects to exercise the purchase rights represented by such Warrant for, and to
purchase thereunder,             * shares of Common Stock of UroGen Corp. and herewith: 
  
 (Check one) 
  
  ̈    makes pay­ment of $_________ therefor; or 
  
  ̈    surrenders __________ shares of
__________ stock of UroGen Corp. or $ __________ of 
         aggregate indebtedness; or 

 
  ̈    elects to “net exercise” the Warrant pursuant to Section 2(b)(ii) of the Warrant and authorizes 
         UroGen Corp. to withhold from issuance the appropriate number of Warrant Shares as specified 
         therein. 
  
 
	 __________________________________________
 
	 (Signature must conform in all respects to name of holder as specified on the face of the Warrant)
 
	 __________________________________________
 
	  
 __________________________________________
 
	             (Address)
 

 

	 	

	 	

  
 Dated: 
  
                                       
                
  
 * Insert here the number of shares as to which the Warrant
is being exercised.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}]]